<DOC>
	<DOCNO>NCT00118053</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , trastuzumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Drugs use chemotherapy , docetaxel carboplatin , work different way stop growth tumor cell , either kill cell stop divide . Giving trastuzumab together docetaxel carboplatin may kill tumor cell . PURPOSE : This phase II trial study well give trastuzumab together docetaxel carboplatin work treat woman stage II , stage III , inflammatory breast cancer .</brief_summary>
	<brief_title>Trastuzumab , Docetaxel , Carboplatin Treating Women With Stage II , Stage III , Inflammatory Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine antitumor activity trastuzumab ( Herceptin^® ) , docetaxel , carboplatin , measure tumor response rate , woman previously untreated HER2/neu-positive stage IIB , IIIA , IIIB , IIIC inflammatory breast cancer . Secondary - Determine pathological complete response patient treat regimen . - Determine disease-free survival patient treat regimen . - Determine toxicity regimen patient . - Determine pathologic molecular marker predict efficacy regimen patient . OUTLINE : This non-randomized , multicenter study . - Course 1 ( day 1-28 ) : Patients receive trastuzumab ( Herceptin^® ) IV 30-90 minute day 1 , 8 , 15 , 22 docetaxel IV 1 hour carboplatin IV 30-60 minute day 8 . - Course 2-6 : Patients receive trastuzumab IV 30 minute day 1 , 8 , 15 course 2-5 day 1 , 8 , 15 , 22 course 6 . Patients also receive docetaxel IV 1 hour carboplatin IV 30-60 minute day 1 . Treatment repeat every 21 day 5 additional course ( 6 course total ) absence disease progression unacceptable toxicity . Three week completion course 6 , patient undergo restaging . Patients local operable disease undergo modify radical mastectomy lumpectomy axillary node dissection follow radiotherapy . Patients also receive trastuzumab IV every 3 week 52 week total treatment ( include 6 course trastuzumab , docetaxel , carboplatin ) absence disease progression unacceptable toxicity . Patients local operable disease continue receive trastuzumab . PROJECTED ACCRUAL : A total 13-43 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Inflammatory Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm breast cancer , meet 1 follow stage criterion : Stage IIB ( T3 , N0 ) Stage IIIA ( N0N2 ) Stage IIIB ( T4 , N02 ) Stage IIIC Inflammatory breast cancer HER2/neupositive disease fluorescence situ hybridization Biopsyaccessible tumor Measurable disease physical examination xray No stage IV disease Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age 18 Sex Female Menopausal status Not specify Performance status ECOG 02 Life expectancy At least 8 week Hematopoietic Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hepatic Meets 1 follow criterion : SGOT SGPT ≤ 5 time upper limit normal ( ULN ) AND alkaline phosphatase normal SGOT SGPT ≤ 1.5 time ULN AND alkaline phosphatase ≤ 2.5 time ULN SGOT SGPT normal AND alkaline phosphatase ≤ 5 time ULN Bilirubin normal Renal Creatinine normal No preexisting clinically significant renal disease related malignancy Cardiovascular Ejection fraction ≥ 50 % MUGA No preexist clinically significant cardiac disease relate malignancy No history congestive heart failure Pulmonary No preexist clinically significant pulmonary disease related malignancy Gastrointestinal No severe malnutrition No intractable emesis Neurologic No preexist clinically significant neurologic disease relate malignancy No peripheral neuropathy ≥ grade 2 No nerve damage diabetes Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective nonhormonal contraception 4 week completion study treatment No know allergic reaction study drug No active infection No malignancy except adequately treat basal cell squamous cell skin cancer carcinoma situ cervix No preexisting clinically significant disease relate malignancy No serious significant medical condition would preclude study participation No contraindication study treatment PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent immunotherapy Chemotherapy No prior chemotherapy malignancy No concurrent chemotherapy Endocrine therapy No concurrent hormonal therapy malignancy Radiotherapy No concurrent radiotherapy Surgery No concurrent surgery malignancy Other More 2 week since prior concurrent herbal remedy aspirincontaining product No concurrent investigational commercial agent therapy malignancy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>inflammatory breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
</DOC>